Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease associated with comorbid thymoma in 10%-15% of cases. Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) expressed by T cells downregulates T-cell-mediated immune response. Polymorphisms in the CTLA4 gene have been associated with the development of M...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Data de publicação: | 2023 |
| País: | España |
| Recursos: | Universitat Autònoma de Barcelona |
| Repositório: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglês |
| OAI Identifier: | oai:ddd.uab.cat:271384 |
| Acesso em linha: | https://ddd.uab.cat/record/271384 https://dx.doi.org/urn:doi:10.1212/NXI.0000000000200085 |
| Access Level: | Acceso aberto |
| Palavra-chave: | CTLA-4 Antigen Forkhead Transcription Factors Myasthenia Gravis Probability Retrospective Studies Thymoma Thymus Neoplasms |
| id |
ES_4f605dc1e57d69fb9ae0e0f8629f0857 |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:271384 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis |
| title |
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis |
| spellingShingle |
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis Álvarez Velasco, Rodrigo|||0000-0002-4743-7205 CTLA-4 Antigen Forkhead Transcription Factors Myasthenia Gravis Probability Retrospective Studies Thymoma Thymus Neoplasms |
| title_short |
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis |
| title_full |
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis |
| title_fullStr |
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis |
| title_full_unstemmed |
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis |
| title_sort |
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis |
| dc.creator.none.fl_str_mv |
Álvarez Velasco, Rodrigo|||0000-0002-4743-7205 Dols Icardo, Oriol|||0000-0003-2656-8748 El Bounasri, Shaima|||0000-0003-0384-1633 López Vilaró, Laura|||0000-0002-5428-8017 Trujillo Reyes, Juan Carlos|||0000-0002-3370-0869 Reyes-Leiva, David|||0000-0001-6983-7130 Suarez-Calvet, Xavier|||0000-0002-5314-6607 Cortés-Vicente, Elena|||0000-0002-1428-1072 Illa, Isabel|||0000-0002-2186-2684 Gallardo, Eduard|||0000-0002-3942-3436 |
| author |
Álvarez Velasco, Rodrigo|||0000-0002-4743-7205 |
| author_facet |
Álvarez Velasco, Rodrigo|||0000-0002-4743-7205 Dols Icardo, Oriol|||0000-0003-2656-8748 El Bounasri, Shaima|||0000-0003-0384-1633 López Vilaró, Laura|||0000-0002-5428-8017 Trujillo Reyes, Juan Carlos|||0000-0002-3370-0869 Reyes-Leiva, David|||0000-0001-6983-7130 Suarez-Calvet, Xavier|||0000-0002-5314-6607 Cortés-Vicente, Elena|||0000-0002-1428-1072 Illa, Isabel|||0000-0002-2186-2684 Gallardo, Eduard|||0000-0002-3942-3436 |
| author_role |
author |
| author2 |
Dols Icardo, Oriol|||0000-0003-2656-8748 El Bounasri, Shaima|||0000-0003-0384-1633 López Vilaró, Laura|||0000-0002-5428-8017 Trujillo Reyes, Juan Carlos|||0000-0002-3370-0869 Reyes-Leiva, David|||0000-0001-6983-7130 Suarez-Calvet, Xavier|||0000-0002-5314-6607 Cortés-Vicente, Elena|||0000-0002-1428-1072 Illa, Isabel|||0000-0002-2186-2684 Gallardo, Eduard|||0000-0002-3942-3436 |
| author2_role |
author author author author author author author author author |
| dc.subject.none.fl_str_mv |
CTLA-4 Antigen Forkhead Transcription Factors Myasthenia Gravis Probability Retrospective Studies Thymoma Thymus Neoplasms |
| topic |
CTLA-4 Antigen Forkhead Transcription Factors Myasthenia Gravis Probability Retrospective Studies Thymoma Thymus Neoplasms |
| description |
Myasthenia gravis (MG) is an autoimmune disease associated with comorbid thymoma in 10%-15% of cases. Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) expressed by T cells downregulates T-cell-mediated immune response. Polymorphisms in the CTLA4 gene have been associated with the development of MG. In this context, we aimed to determine whether CTLA4 expression in the thymoma differs between patients with and without MG and whether CTLA4 gene polymorphisms are associated with these differences. This is a retrospective study of all patients, with and without MG, surgically treated at our institution for thymoma between January 2010 and December 2020. Ten samples were obtained from normal thymuses as controls. The number of CTLA4-positive cells in paraffin-embedded thymoma samples was determined by immunohistochemistry. The presence of follicular-center and regulatory T-cell lymphocytes was determined by immunohistochemistry (B-cell lymphoma [BCL]-6 expression) and double immunofluorescence-based staining of CD4-FOXP3, respectively. We evaluated the association between thymic expression of CTLA4 and the development of MG. We also determined the association between CTLA4 expression and various clinical and prognostic characteristics of MG. We sequenced the CTLA4 gene and evaluated possible associations between CTLA4 polymorphisms and thymic CTLA4 expression. Finally, we assessed the potential association between these polymorphisms and the risk of MG. Forty-one patients with thymoma were included. Of them, 23 had comorbid MG (56.1%). On average, patients with MG had fewer CTLA4-positive cells in the thymoma than non-MG patients: 69.3 cells/mm 2 (95% CIs: 39.6-99.1) vs 674.4 (276.0-1,024.0) cells/mm 2 ; p = 0.001 and vs controls (200.74 [57.9-343.6] cells/mm 2 ; p = 0.02). No between-group differences (MG vs non-MG) were observed in the number of cells positive for BCL6 or CD4-FOXP3. CTLA4 expression was not associated with differences in MG outcome or treatment refractoriness. Two polymorphisms were detected in the CTLA4 gene, rs231770 (n = 30 patients) and rs231775 (n = 17). MG was present in a similar proportion of patients for all genotypes. However, a nonsignificant trend toward a lower CTLA4-positive cell count was observed among carriers of the rs231775 polymorphism vs noncarriers: 77.9 cells/mm 2 (95% CI: -51.5 to 207.5) vs 343.3 cells/mm 2 (95% CI: 126.2-560.4). Reduced CTLA4 expression in thymoma may predispose to a higher risk of developing MG. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2 2023-01-01 2023 2023-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/271384 https://dx.doi.org/urn:doi:10.1212/NXI.0000000000200085 |
| url |
https://ddd.uab.cat/record/271384 https://dx.doi.org/urn:doi:10.1212/NXI.0000000000200085 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.relation.none.fl_str_mv |
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI19-01774 Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 JR19-00037 |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869407816089862144 |
| spelling |
Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia GravisÁlvarez Velasco, Rodrigo|||0000-0002-4743-7205Dols Icardo, Oriol|||0000-0003-2656-8748El Bounasri, Shaima|||0000-0003-0384-1633López Vilaró, Laura|||0000-0002-5428-8017Trujillo Reyes, Juan Carlos|||0000-0002-3370-0869Reyes-Leiva, David|||0000-0001-6983-7130Suarez-Calvet, Xavier|||0000-0002-5314-6607Cortés-Vicente, Elena|||0000-0002-1428-1072Illa, Isabel|||0000-0002-2186-2684Gallardo, Eduard|||0000-0002-3942-3436CTLA-4 AntigenForkhead Transcription FactorsMyasthenia GravisProbabilityRetrospective StudiesThymomaThymus NeoplasmsMyasthenia gravis (MG) is an autoimmune disease associated with comorbid thymoma in 10%-15% of cases. Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) expressed by T cells downregulates T-cell-mediated immune response. Polymorphisms in the CTLA4 gene have been associated with the development of MG. In this context, we aimed to determine whether CTLA4 expression in the thymoma differs between patients with and without MG and whether CTLA4 gene polymorphisms are associated with these differences. This is a retrospective study of all patients, with and without MG, surgically treated at our institution for thymoma between January 2010 and December 2020. Ten samples were obtained from normal thymuses as controls. The number of CTLA4-positive cells in paraffin-embedded thymoma samples was determined by immunohistochemistry. The presence of follicular-center and regulatory T-cell lymphocytes was determined by immunohistochemistry (B-cell lymphoma [BCL]-6 expression) and double immunofluorescence-based staining of CD4-FOXP3, respectively. We evaluated the association between thymic expression of CTLA4 and the development of MG. We also determined the association between CTLA4 expression and various clinical and prognostic characteristics of MG. We sequenced the CTLA4 gene and evaluated possible associations between CTLA4 polymorphisms and thymic CTLA4 expression. Finally, we assessed the potential association between these polymorphisms and the risk of MG. Forty-one patients with thymoma were included. Of them, 23 had comorbid MG (56.1%). On average, patients with MG had fewer CTLA4-positive cells in the thymoma than non-MG patients: 69.3 cells/mm 2 (95% CIs: 39.6-99.1) vs 674.4 (276.0-1,024.0) cells/mm 2 ; p = 0.001 and vs controls (200.74 [57.9-343.6] cells/mm 2 ; p = 0.02). No between-group differences (MG vs non-MG) were observed in the number of cells positive for BCL6 or CD4-FOXP3. CTLA4 expression was not associated with differences in MG outcome or treatment refractoriness. Two polymorphisms were detected in the CTLA4 gene, rs231770 (n = 30 patients) and rs231775 (n = 17). MG was present in a similar proportion of patients for all genotypes. However, a nonsignificant trend toward a lower CTLA4-positive cell count was observed among carriers of the rs231775 polymorphism vs noncarriers: 77.9 cells/mm 2 (95% CI: -51.5 to 207.5) vs 343.3 cells/mm 2 (95% CI: 126.2-560.4). Reduced CTLA4 expression in thymoma may predispose to a higher risk of developing MG. 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/271384https://dx.doi.org/urn:doi:10.1212/NXI.0000000000200085reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI19-01774Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 JR19-00037open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2713842026-06-06T12:50:31Z |
| score |
15,198674 |